Terms: = Lung cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
22 results:
1. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
2. Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease.
Harris KM; Preiss L; Varughese T; Bauer A; Calhoun CL; Treadwell M; Masese R; Hankins JS; Hussain FA; Glassberg J; Melvin CL; Gibson R; King AA;
JAMA Netw Open; 2023 May; 6(5):e2314070. PubMed ID: 37200033
[TBL] [Abstract] [Full Text] [Related]
3. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell lung cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract] [Full Text] [Related]
4. Special issue "The advance of solid tumor research in China": fgfr4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
Gao G; Cui L; Zhou F; Jiang T; Wang W; Mao S; Wu F; Jiang F; Zhang B; Bei T; Xie W; Zhang C; Zhang H; Gao C; Zhao X; Bai Y; Zhou C; Ren S
Int J Cancer; 2023 Jan; 152(1):79-89. PubMed ID: 36062503
[TBL] [Abstract] [Full Text] [Related]
5. Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.
Sitthideatphaiboon P; Teerapakpinyo C; Korphaisarn K; Leelayuwatanakul N; Pornpatrananrak N; Poungvarin N; Chantranuwat P; Shuangshoti S; Aporntewan C; Chintanapakdee W; Sriuranpong V; Vinayanuwattikun C
Sci Rep; 2022 Feb; 12(1):2167. PubMed ID: 35140316
[TBL] [Abstract] [Full Text] [Related]
6. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract] [Full Text] [Related]
7. Development of nomogram based on immune-related gene fgfr4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
Wang L; Ren Z; Yu B; Tang J
J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
[TBL] [Abstract] [Full Text] [Related]
8. fgfr4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S; Thennavan A; East MP; Parker JS; Cejalvo JM; Garay JP; Hollern DP; He X; Mott KR; Galván P; Fan C; Selitsky SR; Coffey AR; Marron D; Brasó-Maristany F; Burgués O; Albanell J; Rojo F; Lluch A; de Dueñas EM; Rosen JM; Johnson GL; Carey LA; Prat A; Perou CM
J Clin Invest; 2020 Sep; 130(9):4871-4887. PubMed ID: 32573490
[TBL] [Abstract] [Full Text] [Related]
9. FGFR1 and fgfr4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract] [Full Text] [Related]
10. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
[TBL] [Abstract] [Full Text] [Related]
11. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract] [Full Text] [Related]
12. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract] [Full Text] [Related]
13. fgfr4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.
Quintanal-Villalonga A; Molina-Pinelo S; Yagüe P; Marrugal Á; Ojeda-Márquez L; Suarez R; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
Lung Cancer; 2019 May; 131():112-121. PubMed ID: 31027687
[TBL] [Abstract] [Full Text] [Related]
14. Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and fgfr4 expression.
Liu J; Zhang Z; Li X; Chen J; Wang G; Tian Z; Qian M; Chen Z; Guo H; Tang G; Huang W; Tian D; Wang D; Nie Y; Fan D; Wu K; Xia L
Oncogene; 2018 Oct; 37(41):5477-5491. PubMed ID: 29884889
[TBL] [Abstract] [Full Text] [Related]
15. A Multi-institutional Analysis of Trimodality Therapy for Esophageal cancer in Elderly Patients.
Lester SC; Lin SH; Chuong M; Bhooshan N; Liao Z; Arnett AL; James SE; Evans JD; Spears GM; Komaki R; Haddock MG; Mehta MP; Hallemeier CL; Merrell KW
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):820-828. PubMed ID: 28476435
[TBL] [Abstract] [Full Text] [Related]
16. Therapeutics Targeting FGF Signaling Network in Human Diseases.
Katoh M
Trends Pharmacol Sci; 2016 Dec; 37(12):1081-1096. PubMed ID: 27992319
[TBL] [Abstract] [Full Text] [Related]
17. Hydrogen-rich water ameliorates bronchopulmonary dysplasia (BPD) in newborn rats.
Muramatsu Y; Ito M; Oshima T; Kojima S; Ohno K
Pediatr Pulmonol; 2016 Sep; 51(9):928-35. PubMed ID: 26845501
[TBL] [Abstract] [Full Text] [Related]
18. fgfr4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer.
Liu R; Li J; Xie K; Zhang T; Lei Y; Chen Y; Zhang L; Huang K; Wang K; Wu H; Wu M; Nice EC; Huang C; Wei Y
Cancer Res; 2013 Oct; 73(19):5926-35. PubMed ID: 23943801
[TBL] [Abstract] [Full Text] [Related]
19. Targeted genetic dependency screen facilitates identification of actionable mutations in fgfr4, MAP3K9, and PAK5 in lung cancer.
Fawdar S; Trotter EW; Li Y; Stephenson NL; Hanke F; Marusiak AA; Edwards ZC; Ientile S; Waszkowycz B; Miller CJ; Brognard J
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12426-31. PubMed ID: 23836671
[TBL] [Abstract] [Full Text] [Related]
20. FGF receptors: cancer biology and therapeutics.
Katoh M; Nakagama H
Med Res Rev; 2014 Mar; 34(2):280-300. PubMed ID: 23696246
[TBL] [Abstract] [Full Text] [Related]
[Next]